Castle Biosciences

Castle Biosciences, VHA Expand Supply Contract to Cover Full Skin Cancer Test Portfolio

Castle Biosciences to Acquire AltheaDx for $65M

In Brief This Week: Castle Biosciences, Roche, Biocept, Ellume, Accelerate Diagnostics, and More

Castle Biosciences Q4 Revenues Grow 45 Percent

Castle Biosciences Working With NCI on SEER Registry Study of DecisionDx-Melanoma

360Dx Top 30 Plummets 17 Percent in January

CareDx, Castle Bio, Lucira Health, Others Announce Preliminary Q4, FY21 Earnings Results

360Dx Index Follows Larger Market Trends, Drops 4 Percent in November

Castle Biosciences Q3 Revenues Rise 54 Percent

Castle Biosciences Acquires Cernostics for up to $80M

Broader Markets Weigh Down Dx Stocks, 360Dx Index Falls 4 Percent in September

Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test

Castle Biosciences Awarded VA Supply Contract for Melanoma Test

Castle Biosciences Q2 Revenues Rise 79 Percent

360Dx Index Up 7 Percent in June, Rebounding From May Downturn

Castle Biosciences Receives NYS DOH Approval for Skin Cancer Diagnostic

Castle Biosciences Q1 Revenues Up 31 Percent